Share
array:24 [ "pii" => "S2445146021000261" "issn" => "24451460" "doi" => "10.1016/j.vacune.2020.12.001" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "177" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:127-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S1576988721000066" "issn" => "15769887" "doi" => "10.1016/j.vacun.2020.12.003" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "177" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:127-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "The future role of pharmacists and pharmacovigilance after the advent of the COVID-19 pandemic" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "127" "paginaFinal" => "128" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Rol de farmacéuticos y farmacovigilancia tras la aparición de la pandemia de COVID-19" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. La Gatta, F. Ghidinelli" "autores" => array:2 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "La Gatta" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Ghidinelli" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2445146021000261" "doi" => "10.1016/j.vacune.2020.12.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000261?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988721000066?idApp=UINPBA00004N" "url" => "/15769887/0000002200000002/v1_202106120702/S1576988721000066/v1_202106120702/en/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2445146021000236" "issn" => "24451460" "doi" => "10.1016/j.vacune.2020.08.001" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "159" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:129-30" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Simultaneous occurrence of seasonal influenza virus and SARS CoV-2 strains" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "129" "paginaFinal" => "130" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Circulación simultánea de virus de la gripe estacional y cepas SARS CoV-2" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Talebi Bezmin Abadi, N. Petrosillo, A.R. Kavoor" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Talebi Bezmin Abadi" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Petrosillo" ] 2 => array:2 [ "nombre" => "A.R." "apellidos" => "Kavoor" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1576988720300406" "doi" => "10.1016/j.vacun.2020.08.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988720300406?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000236?idApp=UINPBA00004N" "url" => "/24451460/0000002200000002/v1_202106241110/S2445146021000236/v1_202106241110/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2445146021000194" "issn" => "24451460" "doi" => "10.1016/j.vacune.2021.05.005" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "184" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:125-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the editor</span>" "titulo" => "Governments and vaccination against COVID-19" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "125" "paginaFinal" => "126" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Los gobiernos y la vacunación contra la COVID-19" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L.A. Javier Silva, E.A. Rosario Pacahuala" "autores" => array:2 [ 0 => array:2 [ "nombre" => "L.A." "apellidos" => "Javier Silva" ] 1 => array:2 [ "nombre" => "E.A." "apellidos" => "Rosario Pacahuala" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1576988721000133" "doi" => "10.1016/j.vacun.2021.03.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988721000133?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000194?idApp=UINPBA00004N" "url" => "/24451460/0000002200000002/v1_202106241110/S2445146021000194/v1_202106241110/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "The future role of pharmacists and pharmacovigilance after the advent of the COVID-19 pandemic" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "127" "paginaFinal" => "128" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A. La Gatta, F. Ghidinelli" "autores" => array:2 [ 0 => array:4 [ "nombre" => "A." "apellidos" => "La Gatta" "email" => array:1 [ 0 => "alessandra.lagatta03@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "F." "apellidos" => "Ghidinelli" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Recordati S.p.A., Milan, Italy" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Spedali Civili di Brescia, Brescia, Italy" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Rol de farmacéuticos y farmacovigilancia tras la aparición de la pandemia de COVID-19" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The unforeseen arrival of the coronavirus disease 2019 (COVID-19) has completely subverted our daily life.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Pharmacists have been representing a crucial role in the fight against SARS-CoV2 virus.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The importance of these figures has been extensively confirmed during this pandemic.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">This health crisis has created pandemic-related challenges and it has laid the foundations for a future massive change in this world.</p><p id="par0025" class="elsevierStylePara elsevierViewall">First, when the vaccine against COVID-19 is released, pharmacists will be assigned the role of primary frontline health workers in order to provide immunization to people, as demonstrated by community pharmacists who have been well-placed to provide accessible coverage in the past.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Second, as reported by John <span class="elsevierStyleSmallCaps">C</span>. Hayden et al., social distancing has obliged pharmacists to reinvent the way by which they dispense advice and medications.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">For example, virtual consultations have become common, especially among fragile people. In addition, the implementation of systems to provide drugs to patients was necessary to reduce non-essential medical and pharmaceutical visits and to maintain a good quality of service.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Third, some innovations have been introduced in many countries and they may be preserved in the future, including the electronic prescriptions with primary care eliminating the legislative requirement for paper scripts.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Thus, pharmacists can provide a decisive help to health care system in this pandemic.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Not only has this pandemic conferred new opportunities among pharmacies and patients, but also it has opened new scenarios in the field of pharmacovigilance.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Monitoring the efficacy and safety profiles of medications constitutes a priority for healthcare professionals and patients, especially during the COVID-19 period for drugs administered to treat this infection in ‘off-label use’.</p><p id="par0060" class="elsevierStylePara elsevierViewall">Unfortunately, there is not currently enough data to create worldwide guidelines for a controlled and safe use of all medications administrated for the treatment of COVID-19 infection, outlining the increasing need to promote scientific research.</p><p id="par0065" class="elsevierStylePara elsevierViewall">It should be useful to control patient safety by rapid reporting of adverse drug reactions (ADRs).</p><p id="par0070" class="elsevierStylePara elsevierViewall">This aspect, for example, may be achieved by drug information services that provide 24-h professional advice to patients and healthcare workers after being exposed to medications, as reported by Tuccori et al.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Some hospitals have already commenced to evaluate the incidence, type and risk factors associate with ADRs among patients with COVID-19.</p><p id="par0080" class="elsevierStylePara elsevierViewall">A retrospective study with two hundred seventeen patients with COVID-19 was conducted by the First Hospital of Changsha in China.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">It was demonstrated that the prevalence of ADRs was approximately 37% in patients treated with lopinavir, umifenovir and chloroquine, emphasizing the need of active monitoring of adverse reactions that can occur to patients with COVID-19.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Another increasing point of interest in pharmacovigilance concerning the ADRs is represented by the poor adherence of patients to anti-COVID-19 medications.</p><p id="par0095" class="elsevierStylePara elsevierViewall">The correct identification of risk factors for the onset of adverse reactions is basically vital to choose the most appropriate antiretroviral regimen for the treatment of patients.</p><p id="par0100" class="elsevierStylePara elsevierViewall">A rapid signaling of all ADRs related to anti-COVID-19 medications can facilitate the role of health care workers in the COVID-19 era and, thus, increase the level of patients’ adherence.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacists and COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Elbeddini" 1 => "T. Prabaharan" 2 => "S. Almasalkhi" 3 => "C. Tran" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Pharm Policy Pract" "fecha" => "2020" "volumen" => "3" "paginaInicial" => "1" "paginaFinal" => "4" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Integrating pharmacies into public health program planning for pandemic influenza vaccine response" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.J. Fitzgerald" 1 => "Y. Kang" 2 => "C.B. Bridges" 3 => "T. Talbert" 4 => "S.J. Vagi" 5 => "B. Lamont" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2016.09.020" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2016" "volumen" => "34" "paginaInicial" => "5643" "paginaFinal" => "5648" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27686834" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The challenges of COVID-19 for community pharmacists and opportunities for the future" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.C. Hayden" 1 => "R. Parkin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1017/ipm.2020.52" "Revista" => array:2 [ "tituloSerie" => "Ir J Psychol Med" "fecha" => "2020" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of the COVID-19 “infodemic” on drug-utilization behaviors: implications for pharmacovigilance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Tuccori" 1 => "I. Convertino" 2 => "S. Ferraro" 3 => "E. Cappello" 4 => "G. Valdiserra" 5 => "D. Focosi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40264-020-00965-w" "Revista" => array:2 [ "tituloSerie" => "Drug Saf" "fecha" => "2020" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence of adverse drug reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Sun" 1 => "X. Deng" 2 => "X. Chen" 3 => "J. Huang" 4 => "S. Huang" 5 => "Y. Li" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0009-9236(99)70116-5" "Revista" => array:5 [ "tituloSerie" => "Clin Pharmacol Ther" "fecha" => "2020" "paginaInicial" => "1" "paginaFinal" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9951425" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24451460/0000002200000002/v1_202106241110/S2445146021000261/v1_202106241110/en/main.assets" "Apartado" => array:4 [ "identificador" => "91117" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24451460/0000002200000002/v1_202106241110/S2445146021000261/v1_202106241110/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000261?idApp=UINPBA00004N" ]
